



19th March 2021

Dear Honourable Minister of Health,

Acknowledging the request by Participants for further information regarding vaccine deliveries through COVAX, we are writing to provide you with details on your initial delivery of doses of the AstraZeneca AZD1222 vaccine, as part of your February to May 2021 allocation. This allocation was originally communicated to you on 26th February 2021.

In this early phase of COVID-19 vaccine roll-out through COVAX, vaccine manufacturers require time to scale and optimise their production processes. **This means that projected COVAX deliveries face some delays.** AstraZeneca, which uses a novel supply chain network with sites across multiple continents, is working to shorten its lead times to enable timely supply to Participants.

Of the doses allocated to Georgia through May 2021, you received 43,200 doses in your first delivery. We regret this volume might have been smaller than initially expected. This first delivery quantity is based on an equitable pro-rata share of currently available supply in order to allocate available doses across all Participants that have been allocated doses of this vaccine. Our aim is for all Participants to receive initial doses in the next three weeks.

Based on the latest information received from AstraZeneca, we are aiming to supply the total quantity of allocated doses through to May, as previously communicated to you, **pending operational and supply constraints**. We will continue to update you as more information becomes available on future shipments.

We would also like to draw your attention to WHO's "Considerations for optimizing deployment of AstraZeneca/AZD1222 and SII/Covishield vaccines in a time-limited constrained supply situation" shared with you on 19th March 2021.

Please do not hesitate to reach out to your Gavi Senior Country Manager or COVAX Facility focal point and WHO and UNICEF colleagues copied on this communication with any questions.

Sincerely,

A handwritten signature in blue ink, appearing to read "Aurélia".

Aurélia Nguyen
Managing Director
Office of the COVAX Facility